HK1083759A1 - Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases - Google Patents
Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseasesInfo
- Publication number
- HK1083759A1 HK1083759A1 HK06103961.3A HK06103961A HK1083759A1 HK 1083759 A1 HK1083759 A1 HK 1083759A1 HK 06103961 A HK06103961 A HK 06103961A HK 1083759 A1 HK1083759 A1 HK 1083759A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptor inverse
- compound
- neurodegenerative diseases
- therapeutics
- efficacy
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000002469 receptor inverse agonist Substances 0.000 title abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 2
- 229940076279 serotonin Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000012661 Dyskinesia Diseases 0.000 abstract 2
- 208000028017 Psychotic disease Diseases 0.000 abstract 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 abstract 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000008484 agonism Effects 0.000 abstract 1
- 239000000002 anti-dyskinesia agent Substances 0.000 abstract 1
- 230000003374 anti-dyskinetic effect Effects 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003137 locomotive effect Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000011809 primate model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HK09105896.5A HK1126776A1 (en) | 2003-01-16 | 2006-03-30 | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44140603P | 2003-01-16 | 2003-01-16 | |
US47934603P | 2003-06-17 | 2003-06-17 | |
PCT/US2004/001234 WO2004064738A2 (en) | 2003-01-16 | 2004-01-15 | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1083759A1 true HK1083759A1 (en) | 2006-07-14 |
Family
ID=32776052
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06103961.3A HK1083759A1 (en) | 2003-01-16 | 2006-03-30 | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
HK09105896.5A HK1126776A1 (en) | 2003-01-16 | 2006-03-30 | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09105896.5A HK1126776A1 (en) | 2003-01-16 | 2006-03-30 | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
Country Status (22)
Country | Link |
---|---|
US (17) | US7601740B2 (es) |
EP (2) | EP2009000B1 (es) |
JP (2) | JP5184777B2 (es) |
KR (1) | KR101095939B1 (es) |
CN (3) | CN101780080B (es) |
AT (2) | ATE407117T1 (es) |
AU (1) | AU2004206886B2 (es) |
BR (1) | BRPI0406591B8 (es) |
CA (1) | CA2512639C (es) |
CY (1) | CY1108642T1 (es) |
DE (1) | DE602004016288D1 (es) |
DK (2) | DK1587789T3 (es) |
ES (2) | ES2314362T3 (es) |
HK (2) | HK1083759A1 (es) |
MX (1) | MXPA05007568A (es) |
NZ (1) | NZ541146A (es) |
PT (1) | PT1587789E (es) |
RU (2) | RU2332401C2 (es) |
SG (1) | SG170617A1 (es) |
SI (2) | SI1587789T1 (es) |
WO (1) | WO2004064738A2 (es) |
ZA (1) | ZA200505680B (es) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL151164A0 (en) * | 2000-03-06 | 2003-04-10 | Acadia Pharm Inc | Azacyclic compounds for use in the treatment of serotonin related diseases |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
KR20100008799A (ko) | 2001-12-28 | 2010-01-26 | 아카디아 파마슈티칼스 인코포레이티드 | 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물 |
AU2003247615B2 (en) | 2002-06-24 | 2007-08-09 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) * | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
CA2512639C (en) | 2003-01-16 | 2012-10-30 | Acadia Pharmaceuticals Inc. | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
WO2004064753A2 (en) * | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US7884096B2 (en) * | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US7855195B2 (en) * | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US20050119249A1 (en) * | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
CA2547639A1 (en) * | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7820695B2 (en) * | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
EP2289879B1 (en) * | 2004-09-27 | 2014-11-12 | Acadia Pharmaceuticals Inc. | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
KR20060030175A (ko) * | 2004-10-05 | 2006-04-10 | 경북대학교 산학협력단 | 무정위성 운동 치료용 약학조성물 |
TW200806321A (en) * | 2006-03-24 | 2008-02-01 | Wyeth Corp | New therapeutic combinations for the treatment or prevention of psychotic disorders |
US20080051429A1 (en) * | 2006-04-19 | 2008-02-28 | Van Kammen Daniel | Use of 4-amino-piperidines for treating sleep disorders |
WO2007133802A2 (en) * | 2006-05-15 | 2007-11-22 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
US20080039535A1 (en) * | 2006-08-14 | 2008-02-14 | Wyeth | Methods of identifying agents for treating neurological disorders |
US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
US20100151459A1 (en) * | 2007-01-26 | 2010-06-17 | Jun Soo Kwon | Marker for detecting the proposed efficacy of treatment |
WO2008116024A2 (en) * | 2007-03-19 | 2008-09-25 | Acadia Pharmaceuticals Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
US20080254117A1 (en) * | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
US20100092554A1 (en) * | 2007-04-24 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
GB2463833B (en) * | 2007-06-26 | 2012-02-08 | Parkinson S Inst | Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders |
US20090082342A1 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
JP2010540454A (ja) * | 2007-09-21 | 2010-12-24 | アカディア ファーマシューティカルズ,インコーポレーテッド | ピマバンセリンと他の薬剤との併用投与 |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
LT2364142T (lt) | 2008-10-28 | 2018-06-25 | Arena Pharmaceuticals, Inc. | 5-ht2a serotonino receptoriaus moduliatoriaus kompozicijos, naudotinos su juo susijusių sutrikimų gydymui |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
EP2836213B1 (en) | 2012-04-14 | 2018-07-04 | Intra-Cellular Therapies, Inc. | Fused gamma carbolines |
WO2014085362A1 (en) | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
KR20230023817A (ko) | 2013-12-03 | 2023-02-17 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
TWI690512B (zh) * | 2014-03-07 | 2020-04-11 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
CN104961671B (zh) * | 2014-09-05 | 2018-01-02 | 苏州晶云药物科技有限公司 | N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法 |
EP4385575A2 (en) * | 2015-01-28 | 2024-06-19 | Duke University | Composition comprising methylphenidate and ondansetron for use in substance-related disorders |
EP3271018B1 (en) | 2015-03-02 | 2020-12-23 | Pliva Hrvatska D.O.O. | Processes and intermediates for the preparation of pimavanserin |
CA2992518A1 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
PL3325444T3 (pl) * | 2015-07-20 | 2021-12-06 | Acadia Pharmaceuticals Inc. | Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C |
CZ2015601A3 (cs) | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
CZ2015688A3 (cs) | 2015-10-02 | 2017-04-12 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů |
CN105523993A (zh) * | 2015-12-28 | 2016-04-27 | 重庆两江药物研发中心有限公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用 |
KR102640774B1 (ko) | 2016-03-22 | 2024-02-26 | 헬신 헬쓰케어 에스.에이. | 벤젠술포닐-비대칭 우레아 및 그의 의학적 용도 |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
EP3436010B1 (en) | 2016-03-29 | 2021-03-10 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
CN107343887A (zh) * | 2016-05-06 | 2017-11-14 | 常州爱诺新睿医药技术有限公司 | 一种无定型半酒石酸匹莫范色林与药用辅料的固体分散体及其制备方法 |
CN106179449B (zh) * | 2016-07-18 | 2018-11-13 | 南京工业大学 | 一种碳氮材料负载的钴催化剂及合成哌马色林中间体的方法 |
HRP20191966T4 (hr) | 2016-09-13 | 2022-09-16 | Allergan, Inc. | Stabilizirani neproteinski klostridijalni pripravci toksina |
US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
MX2021013640A (es) | 2017-03-24 | 2022-08-31 | Intra Cellular Therapies Inc | Composiciones novedosas y metodos. |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
KR102608479B1 (ko) | 2017-05-25 | 2023-12-01 | 글리테크 엘엘씨. | Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법 |
AU2018284335A1 (en) | 2017-06-12 | 2020-01-30 | Glytech Llc. | Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists |
CN109111385B (zh) * | 2017-06-23 | 2023-06-30 | 上海翰森生物医药科技有限公司 | 5-ht2a受体抑制剂及其制备方法和应用 |
KR20200043409A (ko) | 2017-08-21 | 2020-04-27 | 아카디아 파마슈티칼스 인코포레이티드 | 질병 치료를 위한 화합물, 이의 염 및 방법 |
EP3672960A2 (en) | 2017-08-21 | 2020-07-01 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and their use for the treatment of diseases |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
CN109568278A (zh) * | 2017-09-28 | 2019-04-05 | 北京万全德众医药生物技术有限公司 | 匹莫范色林片剂及其制备方法 |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
EP3709999B1 (en) | 2017-11-13 | 2024-02-14 | Texas Tech University System | Compositions and methods for treating cancer |
KR102036909B1 (ko) * | 2017-11-28 | 2019-10-25 | 한국과학기술원 | 신규 디스토니아 치료용 약학적 조성물 |
CA3094204A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
IT201800003736A1 (it) | 2018-03-19 | 2019-09-19 | Lundbeck Pharmaceuticals Italy S P A | Processo per la produzione di Pimavanserin |
US20190359985A1 (en) * | 2018-05-22 | 2019-11-28 | John Lawrence Mee | Adjustable method for sustainable human cognitive enhancement |
CN108947891B (zh) | 2018-07-26 | 2021-02-09 | 丽珠集团新北江制药股份有限公司 | 利用三光气安全制备匹莫范色林及其酒石酸盐的方法 |
CA3108553A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
JP7457000B2 (ja) | 2018-08-31 | 2024-03-27 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
IT201800009690A1 (it) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | Processo per la produzione di pimavanserina |
BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
JP2022523774A (ja) | 2019-02-27 | 2022-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脳障害を治療するためのn-置換インドール及び他の複素環化合物 |
CA3138008A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
WO2021016369A1 (en) | 2019-07-22 | 2021-01-28 | Acadia Pharmaceuticals Inc. | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder |
KR102227268B1 (ko) * | 2019-10-07 | 2021-03-12 | 한국과학기술원 | 디스토니아 치료 후보 약물의 신규 스크리닝 방법 |
CN115677723B (zh) * | 2020-01-21 | 2024-06-04 | 瀚远医药有限公司 | 5-ht2a受体拮抗剂及其治疗中枢神经***疾病的应用 |
CN113214141B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其制备和应用 |
WO2021147818A1 (zh) * | 2020-01-21 | 2021-07-29 | 瀚远医药有限公司 | 5-ht2a受体拮抗剂及其治疗中枢神经***疾病的应用 |
WO2021206741A1 (en) * | 2020-04-09 | 2021-10-14 | Delahoussaye Kevin | Modulating neurotransmitter concentration |
EP4186893A1 (en) * | 2020-07-22 | 2023-05-31 | Geneora Pharma (Shijiazhuang) Co., Ltd. | 5-ht2a receptor inhibitor or inverse agonist, preparation method therefor, and application thereof |
US11071739B1 (en) | 2020-09-29 | 2021-07-27 | Genus Lifesciences Inc. | Oral liquid compositions including chlorpromazine |
JP2023549174A (ja) * | 2020-11-04 | 2023-11-22 | グリアセルテック・インコーポレイテッド | クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物 |
CN113292484B (zh) * | 2021-06-04 | 2022-11-15 | 沈阳药科大学 | 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US165225A (en) * | 1875-07-06 | Improvement in hubs | ||
CA684843A (en) | 1964-04-21 | P. Roberts Cecil | Cap aligning mechanism | |
BE794333A (fr) | 1972-01-20 | 1973-07-19 | Wyeth John & Brother Ltd | Composes heterocycliques azotes therapeutiques |
GB1507462A (en) | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
JPS5152176A (es) | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
JPS528517A (en) | 1975-07-09 | 1977-01-22 | Toyo Autom Kk | Fluid line automatic closing system at an earthquake |
GB1586468A (en) | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
CA1140119A (en) | 1978-04-03 | 1983-01-25 | Joseph Torremans | N-heterocyclyl-4-piperidinamines |
US4255432A (en) | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353901A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
GB8527052D0 (en) | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
GB8621892D0 (en) | 1986-09-11 | 1986-10-15 | Lundbeck & Co As H | Organic compound |
FR2642069B1 (fr) | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5214055A (en) | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
US5216165A (en) | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
IT1252227B (it) | 1991-12-17 | 1995-06-05 | Ciba Geigy Spa | Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici |
JPH05208517A (ja) | 1992-01-31 | 1993-08-20 | Nec Corp | 印字制御回路 |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
JPH09501404A (ja) | 1993-05-26 | 1997-02-10 | スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク | 新規化合物 |
US5707798A (en) | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
TW394760B (en) * | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
DE4404183A1 (de) | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
DE69633245T2 (de) | 1995-09-29 | 2005-09-08 | Eli Lilly And Co., Indianapolis | Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation |
WO1997020552A1 (en) * | 1995-12-07 | 1997-06-12 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors |
JP2001519766A (ja) | 1996-04-03 | 2001-10-23 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼの阻害剤 |
DE69729583T2 (de) | 1996-04-17 | 2005-06-09 | Bristol-Myers Squibb Pharma Co. | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren |
US5869488A (en) | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
AU4078997A (en) * | 1996-08-22 | 1998-03-06 | New York University | Cholinesterase inhibitors for treatment of parkinson's disease |
US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
CA2262818A1 (en) | 1996-09-10 | 1998-03-19 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Modified amino acids, pharmaceuticals containing these compounds and methods for their production |
DE19643331A1 (de) | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
BR9808502A (pt) | 1997-05-08 | 2000-05-23 | Smithkline Beecham Corp | Inibidores de protease |
GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
JP2003514763A (ja) | 1998-04-14 | 2003-04-22 | アリーナ・フアーマシユーチカルズ・インコーポレーテツド | 非内在性の構成的に活性化されるヒトセロトニンレセプターおよびその小分子調節物質 |
US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
US6358698B1 (en) | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
CA2315050C (en) | 1998-10-16 | 2009-02-03 | Suntory Limited | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof |
US6150393A (en) | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
US6725038B1 (en) | 1999-01-26 | 2004-04-20 | Nokia Corporation | Method and apparatus for speeding up AAL2 connection setup during handover in advanced cellular networks |
EP1178800A4 (en) | 1999-03-24 | 2002-07-31 | Univ California | TREATMENT OF NEURODEGENERATIVE DISEASES WITH ASPARTYL PROTEASE INHIBITORS |
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
CN1356977A (zh) | 1999-05-17 | 2002-07-03 | 诺沃挪第克公司 | 胰高血糖素拮抗剂/反向激动剂 |
US20050148018A1 (en) | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7022698B2 (en) * | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
US6834122B2 (en) | 2000-01-22 | 2004-12-21 | Kairos Scientific, Inc. | Visualization and processing of multidimensional data using prefiltering and sorting criteria |
IL151164A0 (en) | 2000-03-06 | 2003-04-10 | Acadia Pharm Inc | Azacyclic compounds for use in the treatment of serotonin related diseases |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
DE60141752D1 (de) * | 2000-06-30 | 2010-05-20 | Innogenetics Nv | Differentielle diagnose von neurologischen krankheiten |
KR20030029978A (ko) | 2000-09-25 | 2003-04-16 | 액테리온 파마슈티칼 리미티드 | 말라리아에 유용한 치환된 아미노-아자-사이클로알칸 |
WO2002076464A1 (en) | 2001-03-22 | 2002-10-03 | Arena Pharmaceuticals, Inc. | Anti-psychosis combination |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
KR20100008799A (ko) | 2001-12-28 | 2010-01-26 | 아카디아 파마슈티칼스 인코포레이티드 | 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물 |
EP1509505A2 (en) | 2002-01-23 | 2005-03-02 | Arena Pharmaceuticals, Inc. | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO |
UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
AU2003247615B2 (en) | 2002-06-24 | 2007-08-09 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
WO2004039322A2 (en) | 2002-10-29 | 2004-05-13 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
CA2512639C (en) | 2003-01-16 | 2012-10-30 | Acadia Pharmaceuticals Inc. | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
WO2004064753A2 (en) | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
CA2547639A1 (en) | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
SI1696931T1 (sl) | 2003-12-22 | 2009-08-31 | Acadia Pharm Inc | Amino substituirani diaril(a,d)cikloheptenski analogi kot muskarinski agonisti in postopki za zdravljenje nevropsihiatričnih motenj |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
EP2289879B1 (en) | 2004-09-27 | 2014-11-12 | Acadia Pharmaceuticals Inc. | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
JP5208517B2 (ja) | 2005-01-10 | 2013-06-12 | タヘリ ラドュカ エルエルシー | 血管移植物およびその製造方法 |
JP2008534593A (ja) | 2005-03-30 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法 |
US8572080B2 (en) | 2010-06-04 | 2013-10-29 | Salesforce.Com, Inc. | Methods and systems for analyzing a network feed in a multi-tenant database system environment |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
WO2014085362A1 (en) * | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
US10953000B2 (en) * | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) * | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
US20210077479A1 (en) * | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
-
2004
- 2004-01-15 CA CA2512639A patent/CA2512639C/en not_active Expired - Lifetime
- 2004-01-15 DK DK04702584T patent/DK1587789T3/da active
- 2004-01-15 SG SG200705308-5A patent/SG170617A1/en unknown
- 2004-01-15 AT AT04702584T patent/ATE407117T1/de active
- 2004-01-15 NZ NZ541146A patent/NZ541146A/en not_active IP Right Cessation
- 2004-01-15 ES ES04702584T patent/ES2314362T3/es not_active Expired - Lifetime
- 2004-01-15 MX MXPA05007568A patent/MXPA05007568A/es active IP Right Grant
- 2004-01-15 AU AU2004206886A patent/AU2004206886B2/en not_active Expired
- 2004-01-15 SI SI200430956T patent/SI1587789T1/sl unknown
- 2004-01-15 AT AT08015449T patent/ATE512136T1/de not_active IP Right Cessation
- 2004-01-15 PT PT04702584T patent/PT1587789E/pt unknown
- 2004-01-15 EP EP08015449A patent/EP2009000B1/en not_active Expired - Lifetime
- 2004-01-15 EP EP04702584A patent/EP1587789B1/en not_active Expired - Lifetime
- 2004-01-15 JP JP2006501009A patent/JP5184777B2/ja not_active Expired - Lifetime
- 2004-01-15 SI SI200431728T patent/SI2009000T1/sl unknown
- 2004-01-15 RU RU2005125918/04A patent/RU2332401C2/ru active
- 2004-01-15 DE DE602004016288T patent/DE602004016288D1/de not_active Expired - Lifetime
- 2004-01-15 US US10/759,561 patent/US7601740B2/en active Active
- 2004-01-15 WO PCT/US2004/001234 patent/WO2004064738A2/en active Application Filing
- 2004-01-15 CN CN200910225582.2A patent/CN101780080B/zh not_active Expired - Lifetime
- 2004-01-15 ES ES08015449T patent/ES2367135T3/es not_active Expired - Lifetime
- 2004-01-15 CN CN2004800044790A patent/CN1816524B/zh not_active Expired - Lifetime
- 2004-01-15 CN CN2010105460287A patent/CN102028949A/zh active Pending
- 2004-01-15 KR KR1020057013195A patent/KR101095939B1/ko active IP Right Grant
- 2004-01-15 BR BRPI0406591A patent/BRPI0406591B8/pt active IP Right Grant
- 2004-01-15 DK DK08015449.5T patent/DK2009000T3/da active
-
2005
- 2005-07-14 ZA ZA200505680A patent/ZA200505680B/en unknown
-
2006
- 2006-03-30 HK HK06103961.3A patent/HK1083759A1/xx not_active IP Right Cessation
- 2006-03-30 HK HK09105896.5A patent/HK1126776A1/xx not_active IP Right Cessation
- 2006-05-03 US US11/416,855 patent/US7659285B2/en active Active
- 2006-05-03 US US11/416,594 patent/US7713995B2/en active Active
- 2006-05-03 US US11/416,527 patent/US7732462B2/en active Active
-
2008
- 2008-04-16 RU RU2008115009/04A patent/RU2465267C2/ru active
- 2008-12-03 CY CY20081101402T patent/CY1108642T1/el unknown
-
2010
- 2010-03-10 JP JP2010053450A patent/JP2010174026A/ja active Pending
- 2010-04-13 US US12/759,664 patent/US8008323B2/en not_active Expired - Lifetime
- 2010-04-13 US US12/759,662 patent/US7994193B2/en not_active Expired - Lifetime
-
2011
- 2011-06-27 US US13/169,893 patent/US8227487B2/en not_active Expired - Lifetime
-
2012
- 2012-06-29 US US13/539,011 patent/US8377959B2/en not_active Expired - Lifetime
-
2013
- 2013-01-25 US US13/750,778 patent/US8618130B2/en not_active Expired - Lifetime
- 2013-11-21 US US14/086,838 patent/US8921393B2/en not_active Expired - Lifetime
-
2014
- 2014-11-10 US US14/537,793 patent/US9211289B2/en not_active Expired - Lifetime
-
2015
- 2015-11-06 US US14/935,246 patent/US9566271B2/en not_active Expired - Lifetime
-
2017
- 2017-01-03 US US15/397,582 patent/US10028944B2/en not_active Expired - Lifetime
-
2018
- 2018-06-26 US US16/019,485 patent/US10525046B2/en not_active Expired - Lifetime
-
2019
- 2019-11-18 US US16/687,467 patent/US20200323836A1/en not_active Abandoned
-
2021
- 2021-01-29 US US17/162,476 patent/US20240091212A1/en active Pending
- 2021-09-14 US US17/474,816 patent/US20220241265A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1126776A1 (en) | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases | |
HK1097256A1 (en) | Pyrizdazine derivatives and their use as therapeutic agents | |
EP1861161A4 (en) | APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS | |
ZA200604791B (en) | Hydronopol derivatives as agonists on human ORL1 receptors | |
TWI366469B (en) | Emulsified skin agent for external use | |
CL2011000044A1 (es) | Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria. | |
IL177787A0 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
IL198519A (en) | 7 of the 1, 2, 3, 11- tetrahydro-5, 11-diazo-benzo [a] Trindein-4, 6- deion and its derivatives for use as radiation susceptibility factors for cancer treatment | |
EP1658078A4 (en) | PROCESS FOR THE INTRADERMAL DISTRIBUTION OF THERAPEUTIC AGENTS | |
EP2011513A4 (en) | THERAPEUTIC AGENTS AGAINST ALZHEIMER DISEASE AND CANCER | |
ZA200702690B (en) | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | |
EP2035412A4 (en) | MUSCARINIC RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | |
BRPI0921097A2 (pt) | composto derivado de pirazol-3 carboxamida com atividade de antagonista de receptor 5-ht2b, agente preventivo ou terapêutico, composição farmacêutica e uso do composto ou seu sal farmaceuticamente aceitável e método ou prevenção ou tratamento. | |
EP2365974A4 (en) | FLUORATED BENZOTHIAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND IMAGE-DISPLAYING AGENT FOR THE DIAGNOSIS OF ALZHEIMER DISEASE, WHICH USES THEREOF | |
IL195431A0 (en) | Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia | |
AU2003304410A8 (en) | Agents and methods for treatment of disease by oligosaccharide targeting agents | |
ZA200707487B (en) | Enhanced delivery of skin benefit agents | |
SE0302794D0 (sv) | Novel microparticles for ultrasound contrast imaging and drug delivery | |
EP1951914A4 (en) | DIAGNOSTIC AND THERAPEUTIC METHODS AND AGENTS | |
EP1967201A4 (en) | THERAPEUTIC AGENT FOR SKIN OR SKIN REGENERATING AGENT CONTAINING DESACYL-GHRELINE OR A DERIVATIVE THEREOF AS ACTIVE INGREDIENT | |
EP1578353A4 (en) | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTION DISEASES | |
IL175347A0 (en) | Hydronopol derivatives as agonists on human orl1 receptors | |
EP1958949A4 (en) | THERAPEUTIC AGENT AGAINST HORNHAUT / BINDEHAUT DISEASE | |
DE50300597D1 (de) | Fanghakeneinrichtung für eine Fronthaube eines Kraftfahrzeugs | |
UA11825S (uk) | Куртка жіноча хутрова «моніка». модель 20-мв. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: ADDITION OF INVENTOR: NASH, NORMAN ANDERSSON, CARL-MAGNUS A. ULDAM, ALLAN K |
|
PE | Patent expired |
Effective date: 20240114 |